Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
US Open: āļāļąāļāļāļĩāļŦāļļāđāļāļāļ°āļĨāļāļāļąāļ§ āļĢāļāļāļđ PPI āļāļāļēāļāļēāļĢāļāļđāļāļāļāļāļąāļāļāļēāļāļāđāļāļĄāļđāļĨāđāļĻāļĢāļĐāļāļāļīāļ
āļāļĨāļēāļāļĒāļļāđāļĢāļāļāļ§āļēāļĄāđāļāļ·āđāļāļĄāļąāđāļāļāļ°āļāļ āļāļāļ°āļāļĩāđāļāļąāļāļāļĩāļŦāļļāđāļāļŠāļŦāļĢāļąāļāļŊ āļāļĢāļąāļāļāļąāļ§āļĨāļāļĨāļ
Wells Fargo: āļāļĨāļāļĢāļ°āļāļāļāļāļēāļĢāđāļāļĢāļĄāļēāļŠ 4 āļāđāļēāļāļīāļāļŦāļ§āļąāļ āđāļāđāđāļāļ§āđāļāđāļĄāļāļĩ 2026 āļāļ§āļāđāļŦāđāļāļīāļāļāļāļēāļāļēāļĢāļāļķāļāđāļāļāļēāļŠāđāļŦāļĄāđ ðĄðïļ
āļŦāļļāđāļ Saab āļāļļāđāļāđāļĢāļ āļĢāļąāļāđāļĢāļāļŦāļāļļāļāļāļēāļāļāļēāļĢāđāļāļīāđāļĄāļāļāļāļĢāļ°āļĄāļēāļāļāļĨāļēāđāļŦāļĄāđāļāļŠāđāļāļāļāļīāđāļāđāļ§āļĩāļĒ ð
